Novo Nordisk has launched its Wegovy weight-loss pill in the US at lower prices than injections. The once-daily pill is the first GLP-1 tablet approved and targets appetite suppression. Self-pay patients can access starting doses for $149 a month, far below injectable costs. The drug aims to appeal to patients seeking needle-free, affordable treatment options. Novo hopes the pill will regain market share lost to rivals like Eli Lilly. Shares rose after the launch, despite long-term competitive pressure. The pill is available at major pharmacies and telehealth platforms nationwide. Approval has so far been limited to the US, with UK regulators still reviewing the drug.
Novo Nordisk Launches Wegovy Pill in US, Intensifying Weight-Loss Drug Price War
Andrew Rogers
Andrew Rogers is a freelance journalist based in the USA, with over 10 years of experience covering Politics, World Affairs, Business, Health, Technology, Finance, Lifestyle, and Culture. He earned his degree in Journalism from the University of Florida. Throughout his career, he has contributed to outlets such as The New York Times, CNN, and Reuters. Known for his clear reporting and in-depth analysis, Andrew delivers accurate and timely news that keeps readers informed on both national and international developments.
